Pharmacokinetic Drug Interactions with Nevirapine

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00126334-200309011-00003PMID 14562853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efavirenz

  2012cited by this paper
• Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

  2003cited by this paper
• Therapeutic drug monitoring in HIV infection: current status and future directions

  2002cited by this paper
• Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

  2002cited by this paper
• A pharmacophore for human pregnane X receptor ligands.

  2002cited by this paper
• Interactions among drugs for HIV and opportunistic infections.

  2001cited by this paper
• Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors

  2001cited by this paper
• High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

  2001cited by this paper
• Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.

  2001cited by this paper
• The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.

  2001cited by this paper
• Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin

  2001cited by this paper
• Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin*

  2001cited by this paper
• Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors

  2001cited by this paper
• Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes.

  1999cited by this paper
• Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.

  1999cited by this paper
• Nelfinavir Mesylate: A Protease Inhibitor

  1999cited by this paper
• Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

  1999cited by this paper
• Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

  1999cited by this paper
• Drug treatment of lipid disorders.

  1999cited by this paper
• Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection

  1999cited by this paper
• Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

  1999cited by this paper
• HIV-protease inhibitors.

  1998cited by this paper
• Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.

  1998cited by this paper
• The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.

  1998cited by this paper
• Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.

  1998cited by this paper
• Lack of pharmacokinetic interaction between nelfinavir and nevirapine.

  1998cited by this paper
• A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

  1998cited by this paper
• Ritonavir

  1998cited by this paper
• Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors

  1997cited by this paper
• Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

  1997cited by this paper
• CYP3A gene expression in human gut epithelium.

  1994cited by this paper
• Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

  1991cited by this paper
• Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem.

  1990cited by this paper

• Consideration of Nevirapine Analogs To Reduce Metabolically Linked Hepatotoxicity: A Cautionary Tale of the Deuteration Approach

  2023cites this paper
• Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes

  2019cites this paper
• Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors

  2018cites this paper
• Drug-drug interactions between antiretrovirals and bedaquiline

  2017cites this paper
• Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children

  2016cites this paper
• Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.

  2016cites this paper
• The pharmacokinetics of lumefantrine in adults on nevirapine-based antiretroviral therapy

  2015cites this paper
• Considerations in methadone dosing for opioid addiction

  2014cites this paper
• Population Pharmacokinetic-Pharmacodynamic Modelling of Antimalarial Treatment

  2014cites this paper
• Efavirenz-Based Antiretroviral Treatment Patients Receiving Nevirapine-or Isoniazid in Tuberculosis-HIV-Coinfected Pharmacokinetics of Rifampin and

  2014cites this paper
• Steady State Metabolites following a Single Dose and at Pharmacokinetics of Phase I Nevirapine

  2014cites this paper
• Pharmacokinetics of Rifampin and Isoniazid in Tuberculosis-HIV-Coinfected Patients Receiving Nevirapine- or Efavirenz-Based Antiretroviral Treatment

  2014cites this paper
• Pharmacokinetics of twice-daily versus once-daily dosing with granular slow-release para-aminosalicylic acid in adults on second-line anti-tuberculosis and antiretroviral treatment

  2013cites this paper
• Buprenorphine Metabolism and Drug–Drug Interactions

  2013cites this paper
• Pharmacokinetics of Phase I Nevirapine Metabolites following a Single Dose and at Steady State

  2013cites this paper
• Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness

  2013cites this paper
• Drug-drug interactions between antiretrovirals and fluconazole in HIV-infected patients

  2012influential citation
• Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

  2012cites this paper
• Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients

  2011influential citation
• Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.

  2011cites this paper
• [Clinical relevance of drug interactions].

  2011cites this paper
• Antiretroviral Drug Interactions: Overview of Interactions Involving New and Investigational Agents and the Role of Therapeutic Drug Monitoring for Management

  2011influential citation
• Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals

  2011cites this paper
• Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

  2011cites this paper
• Spectrophotometric determination of nevirapine using tetrathiocyanatocobalt(II) ion as a reagent

  2010cites this paper
• Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital

  2010cites this paper
• Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

  2010cites this paper
• Lack of clinically significant drug interactions between nevirapine and buprenorphine.

  2010cites this paper
• Interactions between HIV infection and malaria in children living in sub-Saharan Africa in the era of widening access to improved interventions

  2010cites this paper
• A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

  2009cites this paper
• Maternal outcomes following introduction of antiretroviral therapy in the public sector: a prospective study at a tertiary hospital in the Eastern Cape.

  2009cites this paper
• Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.

  2009cites this paper
• A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse-Transcriptase Inhibitor–Based Regimens in HIV-Infected Patients Receiving Rifampicin: The N 2 R Study

  2009cites this paper
• Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers

  2009influential citation
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects

  2008cites this paper
• Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

  2008cites this paper
• Clinical Manual of Drug Interaction Principles for Medical Practice

  2008cites this paper
• Pharmacokinetics and 48-Week Efficacy of Nevirapine: 400 mg Versus 600 mg per day in HIV–Tuberculosis Coinfection Receiving Rifampicin

  2008cites this paper
• Interactions between antiretroviral agents and those used to treat tuberculosis

  2008cites this paper
• Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.

  2007cites this paper
• Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica

  2007cites this paper
• Nevirapine Concentration in Nonstimulated Saliva: An Alternative to Plasma Sampling in Children with Human Immunodeficiency Virus Infection

  2007cites this paper
• [Approach to evaluating the clinical relevance of drug interactions in HIV-infected patients].

  2007cites this paper
• A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.

  2006cites this paper
• Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision.

  2006cites this paper
• Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

  2005cites this paper
• Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005.

  2005cites this paper
• Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir

  2005cites this paper
• Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study

  2005influential citation
• Nevirapine in the treatment of HIV

  2004cites this paper
• Novedades en anticoncepción

  2004cites this paper
• Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).

  2004cites this paper
• Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.

  2004cites this paper
• Med-psych drug-drug interactions update.

  2002cites this paper